• Safeer Khan Khattak
  • Saif Ullah Mehsud
  • Irfan Zafar Haider
  • Musarrat Rauf Burki


Background: Pharmacoeconomics has been defined as: the description and analysis of the cost ofdrug therapy to health care systems and society. Aim was to observe the Medication Therapy onthe basis of Phamacoeconomics Analysis and to save the economic resources. Methods: ThisDescriptive Cross sectional study was conducted at Ayub Teaching Hospital and CombinedMilitary Hospital, Abbottabad, from May–August 2011. The case histories of 100 patients werescrutinized thoroughly specially with reference to socioeconomic history, Clinical laboratory tests,Medication history and treatment at hospital and discharge medications. After their collection,these case histories were analyzed with respect to Phamacoeconomics and compared with theworld literature. Result: A total of 100 patients were studied. Pharmacoeconomic analysis showsthat in 49 Patients’ medications were according to international standards while in 51 patients’medications prescribed were irrational. Conclusion: Mutual interaction between physician,surgeon, other healthcare professionals, and clinical pharmacist is necessary to assure rationalmedication therapy and positive response to therapy of each patient.Keywords: Pharmacoeconomics, Rational Therapy


Trask LS. Pharmacoeconomics Principle Methods and

Applications, In Posey LM, (Ed). Pharmacotherapy-A

Pathophysiologic Approach 8th Editon, USA: McGraw Hill;

p. 1–3.

J Cooke. Pharmacoeconomics, In. Walker R, Whittlesea C,

(Eds). Clinical Pharmacy and Therapeutics. 5th Edition, USA:

Elsevier Health Sciences; 2011. p.91–101.

Shargel L, Mutnick AH. Pharmacoeconomics. In: Souney PF,

Swanon LN, (Eds), Comprehensive Pharmacy Review. 7th

Edition, Philedphia: Lipponcott Williams and Wilkins; 2009.

Sanchez LA. Pharmacoeconomic principles and methods:

Conducting pharmacoeconomic evaluations in a hospital

setting. Hosp Pharm 1995;30:412–28.

Townsend RJ. Post marketing drug research and

development, Drug Intell Clin Pharm 1987; 21(1 pt 2):134–6.

Bootman JL, Wertheimer A, Zaske D, Rowland C.

Individualizing gentamicin dosage regimens in burn patients

with gram-negative septicemia: a cost-benefit analysis. J

Pharm Sci 1979;68:267–72.

McGhan W, Rowland C, Bootman JL. Cost-benefit and costeffectiveness: methodologies for evaluating innovation

pharmaceutical services. Am J Hosp Pharm 1978;35:133–40.

Bashir I, Naveed R, Pharmacoeconomics, In: Bashir I

(Editor). Clinical Pharmacy, Concise and Conceptual. 2nd

Edition, Pakistan: Concise Conceptual Publishers; 2011. p.


Scott L. Healthcare update. Mod Health 1994;24:18.

Pamela C. Champe, Drugs affecting the Cardiovascular

System, In. Richerd A. Harvey (Ed), Lippincott Illustrated

Reviews Pharmacology. 4th Edition, Baltimore: Lipponcott

Williams and Wilkins; 2009. p. 183–274.

Joint Formulary Committee (Great Britian), British National

Formulary 56 (BNF 56), UK;2008.

Chambers HF, Deck DH, Anti Mycobacterial Drugs: In:

Bertram G, Katzung, Susan B. Masters, Anthony J. Trevor

(Editors). Basic and clinical pharmacology- 12th Edition,

USA: McGraw Hill Professional; 2011,p. 823–35.

Gillman LS, Gillman AG, Chemotherapy of Microbial

Disease, In: Goodman and Gillman’s The Pharmacological

basis of Therapeutics. 10th Edition. USA: McGraw Hill

Professional; 2001. p. 709–839.

Levinson W. Antimicrobial Drug Resistance, In: Levinson W

(Editor). Review of Medical Microbiology and Immunology,

th Ed, USA: McGraw Hill; 2012, p. 85.

Shargel L, Yu A, Wu-pong S, Bioavailability and

Bioequivalence. In: Applied Biopharmaceutics and

Pharmacokinetics, 5th ed, USA: McGraw Hill Professional;

p. 454.

William Hassan, Hospital Pharmacy 5th Edition, Washington:

Lea and Febiger; 1986, p. 36.

Kessler JM Decision analysis in the formulary process Am J

Health Syst Pharm 1997;54(Suppl 1):S5–8.

Manasse HR. Medication use in an imperfect world: drug

misadventuring as an issue of public policy. Am J Hosp

Pharm 1988; 46:929–44.